Connor, Clark & Lunn Investment Management Ltd. Fibrogen Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $22 Billion
  • Q2 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Fibrogen Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 29,063 shares of FGEN stock, worth $11,915. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,063
Holding current value
$11,915
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024
BUY
$0.89 - $2.36 $25,866 - $68,588
29,063 New
29,063 $25,000
Q3 2023

Nov 13, 2023
BUY
$0.79 - $2.83 $86,467 - $309,751
109,453 New
109,453 $94,000
Q1 2023

May 09, 2023
BUY
$15.95 - $25.18 $426,471 - $673,262
26,738 New
26,738 $498,000
Q2 2022

Aug 05, 2022
SELL
$7.94 - $12.96 $271,500 - $443,154
-34,194 Reduced 74.37%
11,783 $124,000
Q1 2022

May 12, 2022
SELL
$12.02 - $16.79 $244,679 - $341,777
-20,356 Reduced 30.69%
45,977 $553,000
Q4 2021

Feb 10, 2022
BUY
$9.93 - $15.39 $380,845 - $590,252
38,353 Added 137.07%
66,333 $935,000
Q3 2021

Nov 12, 2021
BUY
$10.18 - $26.64 $112,529 - $294,478
11,054 Added 65.31%
27,980 $286,000
Q2 2021

Aug 12, 2021
SELL
$18.57 - $35.68 $318,828 - $612,589
-17,169 Reduced 50.36%
16,926 $451,000
Q1 2021

May 13, 2021
BUY
$31.0 - $55.72 $114,328 - $205,495
3,688 Added 12.13%
34,095 $1.18 Million
Q4 2020

Feb 16, 2021
BUY
$37.09 - $48.97 $1.13 Million - $1.49 Million
30,407 New
30,407 $1.13 Million
Q4 2019

Feb 12, 2020
SELL
$34.58 - $48.06 $402,857 - $559,899
-11,650 Closed
0 $0
Q3 2019

Nov 13, 2019
BUY
$36.98 - $48.45 $430,816 - $564,442
11,650 New
11,650 $431,000

Others Institutions Holding FGEN

# of Institutions
115
Shares Held
57.5M
Call Options Held
2.14M
Put Options Held
907K
View Full List

About FIBROGEN INC

FGEN Quotes by TradingView
  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $38.4M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email